Suppr超能文献

[使用抗精神病药物期间的吞咽困难?]

[Dysphagia or dysphagias during neuroleptic medication?].

作者信息

Chaumartin N, Monville M, Lachaux B

机构信息

UMD Henri-Colin, EPS Paul-Guiraud, Villejuif, France.

出版信息

Encephale. 2012 Sep;38(4):351-5. doi: 10.1016/j.encep.2011.07.002. Epub 2011 Oct 11.

Abstract

INTRODUCTION

Dysphagia is a common symptom in the general population, and even more among psychiatric patients, but rarely seen as a sign of seriousness. It is a cause of death by suffocation, and more or less serious complications, and therefore should be diagnosed and treated. Among psychiatric patients, organic and iatrogenic aetiologies, as well as risk factors are identified, which worsen this symptom when associated. It is now accepted that neuroleptics can aggravate or cause dysphagia. They act by several pathophysiological ways on the different components of swallowing, which can be identified by dynamic tests in the upper aerodigestive tract endoscopy.

LITERATURE FINDINGS

This symptom is rarely reported by patients and often underestimated by caregivers. The frequency of swallowing disorders is not known. Dysphagia is a cause of complications and an increase in mortality rates among psychiatric patients. It has also been found that the average number of psychotropic drugs in patients who die by cafe coronary is significantly higher than in other patients. There are several phases in swallowing: oral, pharyngeal, and oesophageal. Swallowing disorders can affect each of these phases, or several at once: (a) Extrapyramidal syndrome: dysphagia is present in drug induced Parkinson's syndromes, but prevalence is not known. It is most often associated with another symptom of the extrapyramidal syndrome, but can also be isolated, making its diagnosis more difficult. Dysphagia is due to a slowing down in the oral and pharyngeal reflex, called bradykinesia; (b) Tardive dyskinesia: the oro-pharyngo-oesophageal dyskinesia is the most common type. Oesophageal dyskinesia causes asynchronous and random movements of the oesophagus, resulting in dysphagia. It appears mostly beyond 3 months of treatment with neuroleptics; (c) Acute laryngeal or oesophageal dystonia, associated or not with orofacial dystonia, is characterised by an impairment in the oesophageal muscle contraction and a hypertonia of the upper sphincter of the oesophagus; (d) Polyphagia or "binge eating", is frequent in psychotic patients; (e) Finally, there are risk factors for dysphagia: xerostomia, poor dental status, advanced age, neurological diseases, polypharmacy, sedative drugs, CNS depression, etc., which worsen the symptom.

CASE REPORT

Mr J., aged 28, with no psychiatric history, is admitted to the Unit for Difficult Patients in Villejuif for behavioural disorder with homicide on the street. The patient was restrained by passers-by and suffers a head injury and a fracture of the transverse process of L1 vertebra. A cranial CT scan is performed in the emergency room, it is normal. The patient is not known to psychiatric services, and has never taken neuroleptics. Mr J. is homeless, known in his neighbourhood for "his noisy delirium on the street and repeated alcohol abuse." After being arrested by the police in this context, a first psychiatric examination is conducted. The medical certificate states that his condition is not compatible with custody. Mr J. remains mute; he has stereotyped gestures and strange attitudes. No delusion is verbalized. He receives vials of loxapine 50mg causing sedation. At his arrival in the department, Mr J. has the same clinical picture, with a rigid and inexpressive face, reluctance, major unconformity, poor speech. The search for drugs in urine is positive for cannabis. The diagnosis of schizophrenia is rapidly raised, motivating further prescription of loxapine 300 mg daily in combination with clonazepam 6 mg daily. From the earliest days, dysphagia to solids with choking and regurgitation is noted, aggravated by the increase of loxapine treatment of 450 mg / day to 700 mg / day, 7 days after admission. A physical examination is performed before the worsening of dysphagia, it is normal, and in particular, reveals no extrapyramidal syndrome. An anti-cholinergic corrector is introduced, without clinical improvement. A new physical examination is performed; it is normal except for sedation and a slight deviation of the uvula. Upper gastrointestinal endoscopy shows no anatomical lesion. No functional assessment of swallowing is done however. At this stage, the suspicion of neuroleptic induced dysphagia appears to be the most likely hypothesis. Treatment with loxapine is then stopped, resulting in a very rapid clinical improvement. Aripiprazole 15 mg / d is introduced. Dysphagia does not reoccur.

DISCUSSION

Loxapine is an atypical antipsychotic, with a lower risk of neurological side effects than first generation of antipsychotics. These side effects are however numerous and from diverse pathophysiological mechanisms. Loxapine is an antagonist of dopamine and serotonin which is involved in the regulation of several neurotransmitters, explaining the multiple mechanisms involved in the onset of dysphagia: first, blocking dopamine D2 receptors in the striatum, causing motor side-effects of central origin, in addition to peripheral effects of the molecule, which impairs swallowing. In principle, the antagonist activity on serotonin 5-HT2A receptors increases dopaminergic activity in the striatum, reducing the risk of extrapyramidal symptoms and tardive dyskinesia, without avoiding them completely. In addition to these mechanisms, cholinergic blockade reduces oesophageal mobility and pharyngeal reflex. Moreover, the antihistamine, anti-cholinergic and adrenergic receptor blocking alpha-1 can cause sedation, which aggravates the symptom. Finally, the depression of the bulbar centres reduces the swallowing reflex and gag reflex altering the intake of food.

CONCLUSIONS

The swallowing disorder caused by neuroleptics may occur regardless of the molecule or drug class to which it belongs. It can be found even in the absence of any other neurological signs. It is important to search for the aetiological diagnosis for treatment. At the crossroads of several specialties, swallowing disorders are difficult to diagnose and treat. They are frequently underestimated, partly because patients rarely complain. In our case report, the diagnosis was ascertained by the removal of the medication, without functional evidence, probably by a lack of collaboration between the physician and the endoscopist who had not performed any dynamic investigation of swallowing. This case illustrates the importance of knowing the different mechanisms underlying dysphagia in psychiatric patients, and good communication with gastroenterologists to establish a precise diagnosis of the disorder, and adapt the therapy.

摘要

引言

吞咽困难是普通人群中的常见症状,在精神科患者中更为常见,但很少被视为严重症状。它是窒息致死的原因,会引发或多或少的严重并发症,因此应进行诊断和治疗。在精神科患者中,已确定了器质性和医源性病因以及危险因素,这些因素在相互关联时会加重该症状。目前公认抗精神病药物会加重或导致吞咽困难。它们通过多种病理生理途径作用于吞咽的不同组成部分,这可以通过上呼吸道消化道内镜动态检查来识别。

文献研究结果

该症状很少被患者报告,且常常被护理人员低估。吞咽障碍的发生率尚不清楚。吞咽困难是精神科患者出现并发症和死亡率增加的一个原因。还发现因“咖啡馆冠心病”死亡的患者中,精神药物的平均使用量明显高于其他患者。吞咽有几个阶段:口腔期、咽期和食管期。吞咽障碍可影响这些阶段中的每一个,或同时影响多个阶段:(a)锥体外系综合征:药物诱发的帕金森综合征中存在吞咽困难,但其患病率尚不清楚。它最常与锥体外系综合征的另一种症状相关,但也可能单独出现,这使得其诊断更加困难。吞咽困难是由于口腔和咽部反射减慢,即运动迟缓所致;(b)迟发性运动障碍:口咽食管运动障碍是最常见的类型。食管运动障碍导致食管出现异步和随机运动,从而引起吞咽困难。它大多在使用抗精神病药物治疗3个月后出现;(c)急性喉或食管肌张力障碍,与口面部肌张力障碍相关或不相关,其特征是食管肌肉收缩受损和食管上括约肌张力亢进;(d)多食或“暴饮暴食”,在精神病患者中很常见;(e)最后,存在吞咽困难的危险因素:口干、牙齿状况差、高龄、神经系统疾病、多种药物联用、镇静药物、中枢神经系统抑制等,这些因素会加重症状。

病例报告

J先生,28岁,无精神病史,因在街上有杀人行为障碍被收治于维勒瑞夫疑难患者病房。患者被路人制服,头部受伤,L1椎体横突骨折。在急诊室进行了头颅CT扫描,结果正常。该患者未被精神科服务机构知晓,也从未服用过抗精神病药物。J先生无家可归,在其社区以“在街上吵闹的谵妄和反复酗酒”而闻名。在此情况下被警方逮捕后,进行了首次精神科检查。医疗证明表明他的状况不符合拘留条件。J先生保持沉默;他有刻板动作和奇怪态度。未说出任何妄想内容。他接受了50mg洛沙平注射,出现了镇静作用。入院时,J先生的临床表现相同,面部僵硬且无表情,不情愿,严重不合群,言语不佳。尿液药物检测显示大麻呈阳性。迅速做出了精神分裂症的诊断,促使进一步开具每日300mg洛沙平联合每日6mg氯硝西泮的处方。从最初几天起,就注意到患者吞咽固体食物时有吞咽困难、噎食和反流现象,入院7天后,随着洛沙平治疗量从每日450mg增加到700mg,症状加重。在吞咽困难恶化之前进行了体格检查,结果正常,特别是未发现锥体外系综合征。引入了一种抗胆碱能校正剂,但临床症状未改善。再次进行体格检查;除了镇静和悬雍垂稍有偏移外,结果正常。上消化道内镜检查未发现解剖学病变。然而,未对吞咽进行功能评估。在此阶段,抗精神病药物诱发吞咽困难的怀疑似乎是最有可能的假设。随后停用了洛沙平治疗,临床症状很快得到改善。引入了每日15mg阿立哌唑。吞咽困难未再出现。

讨论

洛沙平是一种非典型抗精神病药物,与第一代抗精神病药物相比,神经学副作用风险较低。然而,这些副作用众多且涉及多种病理生理机制。洛沙平是多巴胺和5-羟色胺的拮抗剂,参与多种神经递质的调节,这解释了吞咽困难发生的多种机制:首先,阻断纹状体中的多巴胺D2受体,除了分子的外周作用外,还会引起中枢性运动副作用,从而损害吞咽功能。原则上,对5-羟色胺5-HT2A受体的拮抗活性会增加纹状体中的多巴胺能活性,降低锥体外系症状和迟发性运动障碍的风险,但并不能完全避免。除了这些机制外,胆碱能阻断会降低食管蠕动和咽部反射。此外,抗组胺、抗胆碱能和α-1肾上腺素能受体阻断会引起镇静,从而加重症状。最后,延髓中枢的抑制会降低吞咽反射和呕吐反射,改变食物摄入。

结论

抗精神病药物引起的吞咽障碍可能发生在任何药物分子或药物类别中。即使没有任何其他神经学体征也可能出现。为了进行治疗,寻找病因诊断很重要。吞咽障碍处于多个专业领域的交叉点,难以诊断和治疗。它们常常被低估,部分原因是患者很少抱怨。在我们的病例报告中,通过停用药物确定了诊断,没有功能方面的证据,这可能是由于医生和内镜医生之间缺乏协作,内镜医生未对吞咽进行任何动态检查。该病例说明了了解精神科患者吞咽困难的不同潜在机制以及与胃肠病学家进行良好沟通以准确诊断疾病并调整治疗的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验